Baird initiated coverage of Haemonetics (HAE) with an Outperform rating and $87 price target
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE:
- Haemonetics participates in a conference call with JPMorgan
- Haemonetics Reports Balanced Earnings with Growth and Challenges
- Haemonetics price target lowered to $105 from $115 at Raymond James
- Haemonetics Reports Mixed Fiscal 2025 Results
- Haemonetics: Buy Rating Affirmed Amid Strong Q4 Performance and Margin Improvements